Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sen. Kennedy Assails Bush On Medicare Costs, Accuses White House Of “Conspiracy”

This article was originally published in The Pink Sheet Daily

Executive Summary

Massachusetts Democrat questions plausibility of White House claim that President Bush was unaware of higher cost projection before December. Kennedy identifies actuarial dispute as part of a pattern of deception.

You may also be interested in...



House Democrats Seek Investigation Concerning Industry’s Link To Abramoff

House Democratic leaders question the role of the Alexander Strategy Group in the budget reconciliation legislation and the passage of the Medicare Modernization Act, including a total of $1.7 mil. in payments to the group by PhRMA.

House Democrats Seek Investigation Concerning Industry’s Link To Abramoff

House Democratic leaders question the role of the Alexander Strategy Group in the budget reconciliation legislation and the passage of the Medicare Modernization Act, including a total of $1.7 mil. in payments to the group by PhRMA.

CMS Projects Annual Medicare Rx Market Of $181 Bil. In 2015

The agency projects that total payments to Medicare Rx plans over fiscal years 2006-2015 will be $1.2 tril. CMS stresses that the new cost projections are consistent with previous estimates, plus two additional years of the drug benefit in action.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059321

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel